Drug intelligence / Profile preview

Metivi

Development stage: Preclinical
Lead developer: Esperante Development
Administration: Ophthalmic

Overview

Metivi (also known as DV409) is a preclinical-stage drug candidate being developed by Disphar International (now Esperante Development, a member of the Sever Life Sciences Group) for ophthalmic indications. It is categorized within the company's "Full Development" pipeline, distinguishing it from their life cycle management and generic (aNDA) projects. While the specific molecular target and mechanism of action have not been publicly disclosed, the drug is part of a specialized portfolio focused on ophthalmology, which also includes candidates for glaucoma.

Brand names: Metivi

Beyond the preview

Go deeper on Metivi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metivi.

Explore the full profile